M&A Deal Summary |
|
|---|---|
| Date | 2022-02-11 |
| Target | Ipsen - Consumer Healthcare Business |
| Sector | Healthcare Services |
| Buyer(s) | Mayoly Spindler |
| Sellers(s) | Ipsen |
| Deal Type | Divestiture |
SEARCH BY
Mayoly Spindler is an independent and international pharmaceutical group with a strong expertise in gastroenterology and dermocosmetics. Mayoly Spindler was founded in 1909 and is based in Chatou, France.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Healthcare Services M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: France M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1929 |
| Sector | Life Science |
| Employees | 5,358 |
| Revenue | 3.6B EUR (2024) |
Ipsen is a research and development pharmaceutical company. It manufactures specialty pharmaceuticals and has a worldwide sales presence. Ipsen focuses on products in the gastro-enterology, neurology and cardiovascular therapeutic areas and has also developed specific expertise in some biotech niches such as endocrinology, oncology, neurology and hematology. Ipsen was founded in 1929 and is based in Boulogne-Billancourt, France.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Healthcare Services M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 2 of 2 |
| Country: France M&A | 2 of 2 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-01 |
Ipsen SA - IPN-1087
Paris, France IPN-1087 is a small molecule targeting neurotensin receptor 1 (NTSR1), a protein expressed on multiple solid tumor types. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-27 |
Epizyme
Cambridge, Massachusetts, United States Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme was founded in 2007 and is based in Cambridge, Massachusetts. |
Buy | $247M |
